** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** NEUROPATHIC PAIN AFFECTS THE QUALITY OF LIFE OF MANY AMERICANS. NON-PHARMACOLOGICAL STRATEGIES SUCH AS BIOACTIVE COMPOUNDS IN FOODS ARE BEING EXPLORED AS THERAPEUTICS BUT CAN ALSO SERVE AS TOOLS TO BETTER UNDERSTAND PAIN MECHANISMS. WE PREVIOUSLY REPORTED GINGER REDUCED NEUROPATHIC PAIN AND FAVORED GUT MICROBIOME IN ANIMALS. THIS STUDY IS TO TEST HOW 2 MONTHS OF GINGER SUPPLEMENTATION WOULD AFFECT INDIVIDUALS WITH SCIATICA. WE PLAN TO RECRUIT DIRECT PERSON-TO-PERSON SONICATION IN CLINICS, HEALTH FAIRS, COMMUNITY EVENTS, FLYERS, NON-SOLICITED EMAIL SYSTEM, CAMPUS ANNOUNCEMENTS, CLINICAL RESEARCH INSTITUTE WEBSITE, LOCAL RADIO, NEWSPAPERS, SENIOR NEWSLETTERS, AND TV SCRIPTS. WE PLAN TO ENROLL APPROXIMATELY 200-250 PATIENTS TO OBTAIN 80-100 QUALIFIED SUBJECTS AT THE START OF THE STUDY. AFTER SCREENING, QUALIFIED PARTICIPANTS WILL BE RANDOMLY ASSIGNED TO A NO-GINGER GROUP OR GINGER GROUP. THIS STUDY WILL FOCUSE ON GUT FUNCATION (GUT MICROBIOTA COMPOSITION, FECAL METABOLITES, AND PLASMA MARKERS FOR LEAKY GUT) (PRIMAYR OUTCOME), BLOOD METABOLIES, AND BRAIN ACTIVITY (SECONDARY OUTCOME). IN ADDITION, THIS STUDY WILL MONITOR SAFETY AS WELL AS THE CHANGES IN DIETARY INTAKE, PHYSICAL ACTIVITY, AND OTC.ALL OUTCOMES WILL BE ASSESSED AT BASELINE AND AFTER 2 MONTHS OF INTERVENTION. DATA WILL BE ANALYZED STATISTICALLY.